Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 4 | Health Economics Review

Fig. 4

From: Cost-effectiveness of expanding the target population of biennial screening for breast cancer from ages 50–69 to 45 and/or 74: A cohort modelling study in the Finnish setting

Fig. 4

Cost-effectiveness plane for expanded strategies compared to the current national screening strategy. Incremental cost-effectiveness ratios (ICER) in the north-east quadrant below or between the diagonal lines representing the willingness-to-pay (WTP) threshold range of €25 000–€50 000 per quality-adjusted life year (QALY) are considered cost-effective

Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us